While we are proud to publicise our survival statistics for various common cancers, we don’t think of our patients as statistics. Our patients are individuals with specific needs and health complexities. No two patients fit in the same box.
Statistics collected about any cancer don’t take into consideration information about individual cases. They do not consider age groups, whether a patient has had previous illness, the extent of cancer at diagnosis, complications experienced, previous treatments or adverse reactions to these treatments or any damage left behind by them. Also not taken into account are patients’ lifestyle choices or genetics.
Creating a statistic or success rate represents a linear approach to cancer, by just looking at this problem from the tumor view, without acknowledging each patient’s unique background.
Nonetheless, our numbers are meant to present a general understanding of what cancers we see and how successful our outcomes have been. More than 50% of our survivors live more than two years.
| Cancer Type | Case Number | Stage I | Stage II | Stage III | Stage IV | Benefit Rate (%) |
|---|---|---|---|---|---|---|
| Lung Cancer | 1067 | 33 | 97 | 408 | 428 | 90% |
| Pancreatic Cancer | 195 | 3 | 11 | 32 | 87 | 93% |
| Breast Cancer | 125 | 2 | 3 | 16 | 67 | 88% |
| Ovarian Cancer | 52 | 0 | 3 | 9 | 28 | 92% |
| Colon Cancer | 47 | 0 | 1 | 5 | 28 | 87% |
| Lymphoma | 40 | 2 | 9 | 8 | 4 | 93% |
| Cervical Cancer | 24 | 1 | 1 | 5 | 12 | 96% |
| Bladder Cancer | 11 | 0 | 1 | 0 | 4 | 100% |
The graph below shows the number of months patients have survived after receiving any treatment at our Center.
Key:
CR= Complete Response | PR= Partial Response | SD=Stable | PD=Progress | Effect rate= CR+PR | Benefit Rate=CR+PR+SD
Including Stage 4 patients, over 90% of our patients have been in the 80-90% benefit rate.
| Cancer Type | Case Number | Stage I | Stage II | Stage III | Stage IV | Not Staged | CR | PR | SD | PD | Effect Rate (%) | Benefit Rate (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lung Cancer | 1067 | 33 | 97 | 408 | 428 | 101 | 17 | 298 | 642 | 110 | 30 | 90 |
| Pancreatic Cancer | 195 | 3 | 11 | 32 | 87 | 62 | 0 | 14 | 168 | 13 | 7 | 93 |
| Breast Cancer | 125 | 2 | 3 | 16 | 67 | 37 | 3 | 33 | 74 | 15 | 29 | 88 |
| Ovarian Cancer | 52 | 0 | 3 | 9 | 28 | 12 | 0 | 12 | 36 | 4 | 23 | 92 |
| Colon Cancer | 47 | 0 | 1 | 5 | 28 | 13 | 0 | 7 | 34 | 6 | 15 | 87 |
| Lymphoma | 40 | 2 | 9 | 8 | 4 | 17 | 6 | 16 | 15 | 2 | 55 | 93 |
| Cervical Cancer | 24 | 1 | 1 | 5 | 12 | 5 | 3 | 3 | 17 | 1 | 25 | 96 |
| Bladder Cancer | 11 | 0 | 1 | 0 | 4 | 6 | 0 | 2 | 9 | 0 | 18 | 100 |
| Esophageal Cancer | 1085 | 10 | 313 | 363 | 341 | 58 | 55 | 242 | 711 | 77 | 27 | 93 |
| Liver Cancer | 463 | 8 | 96 | 121 | 103 | 135 | 0 | 81 | 351 | 31 | 18 | 93 |
| Gastric Cancer | 169 | 6 | 18 | 31 | 86 | 28 | 0 | 27 | 125 | 17 | 16 | 90 |
| Rectal Cancer | 133 | 4 | 12 | 8 | 47 | 62 | 0 | 23 | 98 | 12 | 17 | 91 |
| Cardiac Cancer | 110 | 1 | 14 | 32 | 40 | 23 | 2 | 26 | 74 | 8 | 25 | 93 |
| Kidney Cancer | 33 | 2 | 0 | 2 | 15 | 14 | 0 | 2 | 26 | 5 | 6 | 85 |
| Thyroid Cancer | 24 | 0 | 2 | 3 | 5 | 14 | 0 | 2 | 18 | 4 | 8 | 83 |
| Hypopharyngeal Cancer | 21 | 1 | 1 | 5 | 9 | 5 | 0 | 4 | 15 | 2 | 19 | 90 |
| Nasopharyngeal Cancer | 16 | 0 | 2 | 7 | 3 | 4 | 0 | 3 | 11 | 2 | 19 | 88 |
| Endometrial Cancer | 14 | 0 | 0 | 0 | 9 | 5 | 1 | 3 | 7 | 3 | 29 | 79 |
| Laryngeal Cancer | 11 | 0 | 0 | 2 | 4 | 5 | 0 | 2 | 7 | 2 | 18 | 82 |
| Parotid Gland Cancer | 10 | 0 | 0 | 0 | 5 | 5 | 0 | 3 | 6 | 1 | 30 | 90 |
| Other Cancer | 242 | 1 | 0 | 15 | 53 | 173 | 2 | 44 | 173 | 24 | 19 | 90 |
| Total | 3892 | 74 | 584 | 1072 | 1378 | 784 | 89 | 847 | 2617 | 339 | 24 | 91 |
Side Effects: No except fever
We’ve collected statistics about the benefits of our treatments for over 20 years and compared them to traditional treatments.
| Indication | Survival Rates | Conventional Standard Care | Intratumoral Chemoteraphy | Our Treatments (at least 1 of our treatments) |
|---|---|---|---|---|
| Advanced Pancreatic Cancer
(120 cases) |
6 Month Survival Rate (%) | 27% | 18% | 77% |
| 12 Month Survival Rate (%) | 13% | 9% | 57% | |
| Advanced Lung Cancer
(259 cases) |
6 Month Survival Rate (%) | 39% | 61% | 95% |
| 12 Month Survival Rate (%) | 23% | 33% | 86% | |
| 2 Year Survival Rate (%) | 11% | 7% | 37% | |
| Liver Cancer
(221 cases) |
6 Month Survival Rate (%) | NA | 32% | 61% |
| 12 Month Survival Rate (%) | 17% | 19% | 30% |
Traditional survival rates sources:
